Literature DB >> 6769999

The hepatitis B virus-associated delta antigen: isolation from liver, development of solid-phase radioimmunoassays for delta antigen and anti-delta and partial characterization of delta antigen.

M Rizzetto, J W Shih, J L Gerin.   

Abstract

The delta antigen-antibody (delta Ag/anti-delta) system is associated with type B hepatitis in man. The delta Ag was extracted and solubilized by sonication and treatment with 6 M GuHCl from the nuclei of human liver obtained at autopsy of a delta-positive subject. A microtiter solid-phase radioimmunoassay was developed and used for the partial characterization of delta Ag. Equilibrium centrifugation, gel filtration and chemical and enzymatic treatments revealed delta Ag to be a protein of approximately 68,000 m.w. with a buoyant density of 1.28 g/cm3 in CsCl, stable to heat, acid, nucleases, and glycosidases, and inactivated by alkali and proteases. A standard preparation of delta Ag was used to develop a blocking solid-phase radioimmunoassay for anti-delta.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 6769999

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  40 in total

1.  Randomised controlled trial of adenine arabinoside 5'-monophosphate (ARA-AMP) in chronic hepatitis B virus infection.

Authors:  I V Weller; A S Lok; A Mindel; P Karayiannis; S Galpin; J Monjardino; S Sherlock; H C Thomas
Journal:  Gut       Date:  1985-07       Impact factor: 23.059

2.  Evaluation of commercial enzyme immunoassays for detection of hepatitis delta antigen and anti-hepatitis delta virus (HDV) and immunoglobulin M anti-HDV antibodies.

Authors:  A G Shattock; M C Morris
Journal:  J Clin Microbiol       Date:  1991-09       Impact factor: 5.948

3.  Hepatitis delta virus antigen forms dimers and multimeric complexes in vivo.

Authors:  J G Wang; S M Lemon
Journal:  J Virol       Date:  1993-01       Impact factor: 5.103

4.  Viral superinfection in previously unrecognized chronic carriers of hepatitis B virus with superimposed acute fulminant versus nonfulminant hepatitis.

Authors:  C M Chu; C T Yeh; Y F Liaw
Journal:  J Clin Microbiol       Date:  1999-01       Impact factor: 5.948

5.  Attempted treatment of fulminant viral hepatitis with human fibroblast interferon.

Authors:  F Milazzo; M Galli; P G Fassio; A Cargnel; A Pugliese; P A Tovo; G M Vigevani; R Esposito; A Lazzarin; F Caredda
Journal:  Infection       Date:  1985 May-Jun       Impact factor: 3.553

6.  New principle for the simultaneous detection of total and immunoglobulin M antibodies applied to the measurement of antibody to hepatitis B core antigen.

Authors:  G Angarano; L Monno; T A Santantonio; G Pastore
Journal:  J Clin Microbiol       Date:  1984-06       Impact factor: 5.948

7.  Clinical, biochemical, serological, histological and ultrastructural features of liver disease in drug abusers.

Authors:  I V Weller; D Cohn; A Sierralta; M Mitcheson; M G Ross; L Montano; P Scheuer; H C Thomas
Journal:  Gut       Date:  1984-04       Impact factor: 23.059

8.  Delta infection among patients with chronic hepatitis B in the Stockholm region.

Authors:  G Lindh; O Weiland; B G Hansson; A Svedmyr
Journal:  Infection       Date:  1984 Jan-Feb       Impact factor: 3.553

9.  Permanent HBsAg clearance in chronic hepatitis B viral infection following acute delta superinfection.

Authors:  K P Chin; S Govindarajan; A G Redeker
Journal:  Dig Dis Sci       Date:  1988-07       Impact factor: 3.199

10.  Hepatitis B infections in the Arsi region of Ethiopia.

Authors:  P Pasquini; L Bisanti; L Soldo; P Palladino; C Rozera; E Frontini; A Miozzo; T M Di Gennaro; A Indi; S Conti
Journal:  Eur J Epidemiol       Date:  1988-09       Impact factor: 8.082

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.